Position in ABVX
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$68,821,727
+$1,928,549 QoQ
Shares Held
516,447
-14.0% QoQ
Ownership
0.592%
of shares outstanding
% of Portfolio
13.10%
of 13F equity value
Holder Rank
#30
of 301 holders
Holding Since
Sep 2025
4 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ABVX Over Time
Shares Held
Position Value (USD)
Derivatives in ABVX
reported options exposure · as of Dec 31, 2025CallValue
$1,335,064
CallShares
9,900
PutValue
$0
PutShares
0
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Jun 30, 2026Artia Global Partners LP holds $407,350,933 across 37 Biotechnology names. ABVX ranks #1 (16.9% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ABVX |
Abivax S.A.
This page
|
516,447 | $68,821,727 | |
| 2 | INSM |
INSMED Inc
|
589,052 | $62,804,724 | |
| 3 | TRVI |
Trevi Therapeutics, Inc.
|
2,210,852 | $41,232,389 | |
| 4 | RVMD |
Revolution Medicines, Inc.
|
185,390 | $34,719,839 | |
| 5 | ARGX |
Argenx SE
|
29,739 | $27,590,952 | |
| 6 | TVTX |
Travere Therapeutics, Inc.
|
339,033 | $19,260,464 | |
| 7 | NAMS |
NewAmsterdam Pharma Co N.V.
|
503,936 | $17,078,391 | |
| 8 | DNTH |
Dianthus Therapeutics, Inc. /DE/
|
162,990 | $15,888,265 |
All Filings in ABVX
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $68,821,727 | 516,447 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $66,893,178 | 600,747 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $81,013,736 | 600,747 | Shares | Sole | 2026-02-17 | |
| 2025-12-31 | $1,335,064 | 9,900 | Call | Sole | 2026-02-17 | |
| 2025-09-30 | $19,140,959 | 225,453 | Shares | Sole | 2025-11-14 | |
| No filing history on record for this holder in this stock. | ||||||